Related Experiment Videos
Initial hypertension treatment: one combination fits most?
Insights
Initial combination therapy for hypertension, particularly amlodipine plus an ACE inhibitor, offers superior blood pressure control and cardiovascular protection compared to monotherapy. A novel algorithm proposes single-tablet amlodipine + benazepril for most patients.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Growing global prevalence of uncontrolled hypertension.
- Physician inertia and patient nonadherence contribute to treatment challenges.
- Need for effective antihypertensive strategies.
Discussion:
- Initial combination therapy demonstrates superior efficacy over monotherapy for achieving blood pressure targets, rapidity of control, and patient adherence.
- Evidence suggests amlodipine + angiotensin-converting enzyme inhibitor combinations are most effective in reducing cardiovascular events.
- A novel algorithm proposes initiating treatment with a single amlodipine + benazepril tablet for most hypertensive patients.
Key Insights:
- Combination therapy is more effective than monotherapy for multiple hypertension outcomes.
- Amlodipine + ACE inhibitor combination shows promise for cardiovascular event reduction.
- Streamlined single-tablet therapy may improve patient adherence and outcomes.
Outlook:
- Further outcome trials are needed to validate the proposed amlodipine + benazepril algorithm.
- Investigating the risk/benefit ratio of this streamlined approach in stage I hypertension is crucial.
- Potential for improved global hypertension management through optimized initial treatment strategies.
Abstract:
The absolute number of patients with uncontrolled hypertension is growing worldwide. Many factors may be involved, including physician inertia and patient nonadherence. In this context, we reviewed published studies related to the efficacy and efficiency of starting combination antihypertensive treatment versus mono-therapy. The overall evidence supports that initial combination therapy is more effective for many outcomes (ie, reaching blood pressure targets, rapidity of control, patient adherence, and cardiovascular protection assessed by surrogate markers). The few available published clinical trials and observational studies support that the amlodipine + an angiotensin-converting enzyme inhibitor combination may be the most effective for reducing cardiovascular events. We outline a novel algorithm of starting initial therapy with a single tablet containing amlodipine + benazepril in most patients with hypertension regardless of stage or comorbidities. It is our hypothesis that this streamlined approach is likely to yield an overall positive risk/benefit ratio and that it should be tested in an outcome trial versus accepted monotherapies in stage I hypertension.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension I: Introduction
Antihypertensive Drugs: Vasodilators
Hypertension V: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure V: Medical Management